血液恶性肿瘤Therapeutics Market [By Type (Leukemia (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia), Lymphoma, Multiple Myeloma, and Others); By Therapy (Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others); and By Regions (North America - U.S., Canada; Europe - Germany, UK, France, Italy; Asia-Pacific - China, India, Japan, Australia; Latin America - Brazil, Mexico; Middle East & Africa)]: Market size & Forecast, 2018 – 2025

Report Summary

2017年全球血液学恶性肿瘤治疗市场规模估计为404亿美元，并预计将在预测期内获得显着的牵引力。

血液学恶性肿瘤是癌症中的癌症的形式，其在血液形成组织的细胞中，例如在免疫系统或骨髓的细胞中。几种类型的血液学恶性肿瘤包括白血病，非霍奇金淋巴瘤，霍奇皮淋巴瘤和多发性骨髓瘤。虽然具有特殊的实体瘤，染色体易位是这种疾病的常见起源。这通常导致血液恶性肿瘤诊断和治疗的不同方法。血液恶性恶性肿瘤在2011年组成了9％的新诊断的恶性肿瘤，数据表明淋巴瘤的数据比白血病或骨髓瘤更普遍。

The global hematologic malignancies therapeutics market is majorly driven by the increasing incidences of lifestyle-related diseases. The inactive and unhealthy lifestyle of people resulting in a number of lifestyle-associated diseases requiring appropriate therapy is considered as a major factor in accelerating the growth of the global market. Moreover, growing global numbers of people suffering from leukemia and lymphoma are also augmenting the market growth. For instance, according to leukemia and lymphoma society reports, an estimated combined total of 174,250 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2018.

预计预测期间，预计将越来越关注医疗保健部门的研发活动和发明，以提高全球市场的增长。yabo娱乐vip此外，预计将获得适当的可获得性和先进治疗的消费者之间的认识日益感到越来越高兴为即将到期的期间产生市场参与者的显着增长机会。

Segment Analysis

全球血液学恶性肿瘤治疗市场是在类型，治疗和地理的基础上进行分割。

On the basis of type, the global market is segmented leukemia, lymphoma, multiple myeloma, and others. The leukemia is further segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. On the basis of type, leukemia was estimated to dominate the market. The major market share is due to the availability of products such as Imbruvica, Rituxan, and Glivec, which are estimated to be the highest revenue generating drugs. On the basis of therapy, the global Hematologic Malignancies Therapeutics Industry is segmented into Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others. Amongst all the therapies, chemotherapy is the most commonly used treatment with a particular drug or combination of drugs used.

区域分析

In terms of geography, North America was estimated to dominate the global Hematologic Malignancies Therapeutics Market. The dominance is majorly attributed to the high presence of key market players, availability of branded drugs, established healthcare organization, and increasing government support in the region. However, Asia Pacific is expected to dominate the global market during the forecast period. Increasing awareness about early diagnosis, availability of effective treatment in emerging countries, such as India and China, growing healthcare expenditure, and high unmet clinical needs of patients, are some of the factors anticipated to significantly boost the market in the Asia Pacific.

竞争格局

主要公司正在专注于具有工作方法的小公司，以确保在市场中管理地位，与兼并和收购，关键共同努力和新项目进步有关，以便在业务中获取利润份额。全球市场的一些主要关键参与者包括PFizer，Inc。，F.Hoffmann-La Roche Ltd，Sanofi-Aventis，Bristol-Myers Squibb Company，Abbvie，Inc。，Novartis AG，​​Glaxosmithkline Plc，Celgene Corporation，Johnson＆Johnson Services，Inc.和Takeda Pharmaceutical Company有限公司。